Canaccord analyst Whitney Ijem raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $141 from $114 and keeps a Buy rating on the shares. The firm noted the company shared positive preliminary data from their exploratory Ph2 study of setmelanotide in Prader-Willi Syndrome (PWS), a historically difficult- to-treat disease. As such, they are adding this new opportunity to their model assuming peak sales of $2.1B.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $167 from $141 at Citizens
- Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals
- Promising Phase 2 Results for Rhythm Pharmaceuticals’ Setmelanotide in Prader-Willi Syndrome Boost Buy Rating
- Rhythm Pharmaceuticals price target raised to $150 from $129 at Morgan Stanley
- Rhythm Pharmaceuticals rises 15.6%